CALCIUM DOBESILATE VERSUS MICRONISED PURIFIED FLAVONOID FRACTION OF DIOSMIN IN THE TREATMENT OF CHRONIC VENOUS DISEASE: A RANDOMIZED PROSPECTIVE STUDY

Abstract

Introduction: Chronic venous disease (CVD) of the lower extremities has a substantial effect on quality of life. The clinical, etiology, anatomy, pathophysiology classification (CEAP) is a frequently used classification for CVD. Patients with varicose veins are classified as CEAP class C2. Veno-active drugs (VAD) such as Calcium Dobesilate or Micronised Purified Flavonoid Fraction of Diosmin (MPFF) reduce the symptoms of pain associated with CVD. However, although the effectiveness of VAD is well established, it is controversial. The aims of the this study were to compare the efficacy of two VAD (Calcium dobesilate and MPFF in the treatment of CVD in view of the intended visual analogue scale (VAS) and duplex scanning (DS) changes such as measuring great saphenous vein (GSV) diameter. Materials and methods: A total of 24 patients who had no prior VAD treatment with CEAP class C2, with no family history of CVD were treated; 12 received calcium dobesilate and 12 received MPFF for 60 days. Comorbidities such as hypertension (HT) and diabetes mellitus (DM) were examined. Before and after treatment period, the patients were investigated with DS for diameter of GSV and pain complaint according to VAS were recorded. Results: There were no difference in treatment groups in terms of age, gender, or the comorbidities. For the whole groups, no significant differences were recorded before and after treatment regarding DS parameters. On the other hand, pain was significantly reduced for the group 1 and 2 according to VAS (respectively p=0,04,p=0,03). Conclusion: In this study, pain was reduced in both groups, but no improvement was observed in DS findings. The role of VAD in treatment of patients with CVD needs to be improved in the existing recommendations.